I am a clinician scientist, leading the ovarian and rare cancer laboratory at WEHI and working as a medical oncologist at the Peter MacCallum Cancer Centre, Royal Women’s and Royal Melbourne Hospitals.
My clinical expertise is in gynaecological cancers and coordinating care for patients with rare cancers. I have 25 years’ experience in clinical cancer genetics, working in Familial Cancer Clinics.
My laboratory focuses on making pre-clinical models in which to study drug resistance in rare gynaecological cancers. I set up the national WEHI Stafford Fox Rare Cancer Program in order to facilitate the study of many rare cancer types which are poorly researched. I set up the Australian Rare Cancer Portal so that expert rare cancer care and research could be streamlined for individuals, no matter where they live.
I believe that involving the community in research enhances the purpose of our research and magnifies the benefits of what we do.
Australia, The University of Melbourne, AM MBBS, PhD
Department of Obstetrics and Gynaecology, University of Melbourne
Royal Melbourne and Royal Women’s Hospitals
Peter MacCallum Cancer Centre
2022 Queen’s Birthday Honours, appointed a Member of the Order of Australia
2021 Medical Oncology Group of Australia – Novartis Oncology Cancer Achievement Award
2018 Jeannie Ferris Recognition Award, Gynaecological Cancer, Cancer Australia
2017 Election as Fellow, Australian Academy of Health and Medical Sciences (FAHMS)
2013 Fairfax Media and Westpac Group, 100 Women of Influence Award
2022-2027 Stafford Fox Medical Research Foundation – Ovarian Cancers Research Program: Matching a woman’s ovarian cancer to new treatments
2022-2026 NHMRC Investigator Grant – Super-Responders and Super-Survivors – how to dramatically improve cancer outcomes
2022-2024 Victorian Medical Research Acceleration Fund (Tier 2) – Accelerating translational outcomes based on super-responders from the SOLACE2 trial of immunotherapy priming in ovarian cancer
2021-2026 Stafford Fox Medical Research Foundation – Rare Cancers Research Program: Changing the future for patients with rare cancers
2021-2022 Perpetual Trustees – Studying those who survive multiple cancers
2020-2021 Cancer Council Victoria, Venture Grants Scheme – Multiple primary tumours: immune response and metastasis prevention
2020-2024 Australian Cancer Research Foundation – Program for Resolving Cancer Complexity and Therapeutic Resistance
2018-2022 Australian Genomic Cancer Medicine Centre – Rare Cancer Portal
Chair, Australia New Zealand Gynaecology Oncology Group (ANZGOG), 2022- current
Board member, Cancer Trials Australia, 2021-current
Board member, BioGrid Australia, 2020-current
Board member, Cure Cancer Australia Foundation, 2010-2020
Ho GW^, Kyran EL^, Bedo J^, Wakefield MJ^, Ennis DP, Mirza HB, Vandenberg CV, Lieschke E, Farrell A, Hadla A, Lim R, Dall G, Vince JE, Chua NK, Kondrashova O, Upstill-Goddard R, Bailey U-M, Dowson S, Roxburgh P, Glasspool RM, Bryson G, Biankin AV, Cooke SL, on behalf of the Scottish Genomes Partnership, Ratnayake G, McNallyO, Traficante N, Australian Ovarian Cancer Study, DeFazio A, Weroha J, Bowtell DD, McNeish IA#, Papenfuss AT#, SCOTT CL# and Barker HE#*. Ovarian carcinosarcoma genomics and preclinical models enable identification of eribulin as an effective treatment option for this aggressive cancer. Cancer Research. 2022. Dec 2;82(23):4457-4473. doi: 10.1158/0008-5472.CAN-21-4012. PMID: 36206301. ^joint first authors, #joint senior authors
Nesic K#, Kondrashova O#, Hurley R, McGehee C, Vandenberg CM, Ho GY, Lieschke E, Dall G, Bound N, Shield-Artin K, Radke M, Musafer A, Chai ZQ, Ghamsari MRE, Harrell MI, Kee D, Olesen I, McNally O, Traficante N, Australian Ovarian Cancer Study, DeFazio A, Bowtell DD. Swisher EM, Weroha SJ, Nones K, Waddell N, Kaufmann SH, Dobrovic A#, Wakefield MJ# and SCOTT CL#. Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma. Cancer Research. 2021. 81(18):4709-472
Lee CK, Friedlander ML, Tjokrowidjaja A, Lederman JA, Coleman RL, Mirza MR, Matulonis UA, Pujade-Lauraine E, Bloomfield R, Goble S, Wang P, Glasspool RM, SCOTT CL, on behalf of the Gynecologic Cancer InterGroup Meta-analysis Committee. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive recurrent ovarian cancer: A meta-analysis. Cancer. 2021. Jul 15. 127(14): 2432-2441.
Cheasley D†, Wakefield MJ†, Ryland G†, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Anglesio MS, Au-Yeung G, Böhm M, Bowtell DDL, Brand A, Chenevix-Trench G, Christie M, Chiew Y-E, Churchman M, DeFazio A, Demeo R, Dudley R, Fairweather N, Fedele CG, Fereday S, Fox SB, Gilks CB, Gourley C, Hacker NF, Hadley AM, Hendley J, Ho GY, Hughes S, Hunstman DG, Hunter SM, Jobling TW, Kaufmann SH, Kalli KR, Kennedy CJ, Köbel M, Le Page C, Li J, Lupat R, MacNally OM, McAlpine JN, Mes-Masson AM, Mileshkin L, Provencher DM, Pyman J, Rahimi K, Rowley SM, Salazar C, Samimi G, Saunders H, Semple T, Sharma R, Sharpe AJ, Stephens AN, Thio N, de Cunha Torres MC, Traficante N, Xing Z, Zethoven M, Antill YC*, SCOTT CL*, Campbell IG*, Gorringe KL*. The Molecular Origin and Taxonomy of Mucinous Ovarian Carcinoma. Nature Communications. 2019. 10(1):3935. †joint first authors, *joint senior authors.
Kondrashova* O, Topp M*,Monique, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N, Australian Ovarian Cancer Study, DeFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A*, Wakefield MJ*, SCOTT CL*. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nature Communications. 2018. 9(1):3970. *equal contribution
Kondrashova O*, Nguyen M*, Shield-Artin K*, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O’Malley DM, Oza AM, Sun JX, Robillard L, Maloney L, Bowtell DDL, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin K*, SCOTT CL*. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2017 Jun 6 PMID: 28588062. *equal contribution
Kentwell M, Dow E, Antill Y, Wrede CD, McNally O, Higgs E, Hamilton A, Ananda S, Lindeman GJ, SCOTT CL. Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecol Oncol. 2017. 145(1):130-136. PMID: 28162234
Swisher EM*, Lin KK*, Oza AM, SCOTT CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O’Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA. Rucaparib in relapsed, platinumsensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017 18(1):75-87. PMID: 27908594 *equal contribution.
Topp M, Hartley L, Cook M, Heong V, Boehm E, McShane L, Pyman J, McNally O, Ananda S, Harrell M, Etemadmoghadam D, Galletta L, Alsop K, Mitchell G, Fox SB, Kerr JB, Hutt KJ, Kaufmann SH, Australian Ovarian Cancer Study, Swisher EM, Bowtell DD, Wakefield M, Scott CL. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Molecular Oncol 2014. 8(3):656-68. PMID: 24560445
Kerr JB#, Hutt KJ#, Michalak EM#, Cook M, Vandenberg CJ, Liew SH, Bouillet P, Mills A, Scott CL *, Findlay JK*, Strasser A*. DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require Tap63-mediated induction of Puma and Noxa. Mol Cell. 2012.;48(3):343-52. #joint first author, *joint senior author. Cover Image. PMID: 23000175
Nesic K, Wakefield M, Kondrashova O, Scott CL, McNeish IA. Targeting DNA repair: the genome as a potential biomarker. J Pathol. 2018, 244(5): 586-597. PMID: 29282716
Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: Recent advances and future developments. J Clin Oncol. 2015. 33(12):1397-406. PMID: 25779564
Lodhia K, Hadley H, Haluska P, Scott CL. Prioritizing therapeutic targets using patient-derived xenograft models. Biochim Biophys Acta. Rev on Cancer 2015. 1855(2):223-234. PMID: 25783201
Half of the aggressive ovarian cancer subtype, high-grade serous cancer (HGSC), have abnormalities in DNA repair and should be susceptible to new PARP inhibitor therapy, yet not all those respond.
Team members: Dr Cassandra Vandenberg, Dr Mattew Wakefield
By developing new models of studying human ovarian cancers in the laboratory (patient-derived xenografts, PDX, which have abnormal DNA repair), we are exploring which markers predict which ovarian cancers will respond best to these exciting new treatments and most importantly, how to prevent resistance to PARP inhibitors in some of these cancers.
Many gynaecological cancers are rare and poorly studied. Therefore, specific effective treatments are not available. We have generated pre-clinical models to better understand potential therapeutic targets, such as those involving Epithelial to Mesenchymal Transition.
We collaborate closely with Professor Tony Papenfuss and his team of bioinformaticians.
Team member: Dr Holly Barker
Our starting point is to focus on different types of rare cancers and to look across many types of cancers, to see what is in common for individuals responding well to treatment or surviving better than would be expected.
We collaborate closely with Professor Tony Papenfuss and his team of bioinformaticians and with Professor Magdalena Plebanski, and her team at RMIT.
Team members: Dr Kristy Shield-Artin, Dr Matthew Wakefield